公开(公告)号：US12186387B2

公开(公告)日：2025-01-07

申请号：US18071499

申请日：2022-11-29

Applicant: BioNTech SE

Inventor： Alexander Muik ,  Asaf Poran ,  Kena Anne Swanson ,  Qi Yang ,  Hui Cai ,  Ugur Sahin

IPC: A61K39/215 ,  A61K9/127 ,  A61K39/145 ,  A61K45/06 ,  A61K47/26 ,  C12N15/86 ,  A61K39/00

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-COV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-COV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

公开(公告)号：US12153041B2

公开(公告)日：2024-11-26

申请号：US16301019

申请日：2017-05-10

Applicant: BioNTech SE ,  Tron-Translationale Onkologie an der Universitätsmedizin Der Johannesgutenberg-Universität Mainz

Inventor： Mathias Vormehr ,  Ugur Sahin ,  Barbara Schrörs ,  Martin Löwer ,  Sebastian Boegel

IPC: G01N33/50 ,  A61P35/04 ,  G01N33/53 ,  G01N33/68

Abstract: The present invention relates to methods for predicting peptides or polypeptides such as T cell epitopes useful for immunotherapy such as for vaccination. In particular, the present invention relates to methods for predicting whether peptides or polypeptides such as tumor-associated antigens or epitopes, in particular tumor-associated neoantigens or neoepitopes, are immunogenic and, in particular, useful for immunotherapy such as for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.

公开(公告)号：US20240383947A1

公开(公告)日：2024-11-21

申请号：US18287608

申请日：2022-04-20

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Alexander Muik

IPC: C07K14/005 ,  A61K39/00 ,  A61K39/215 ,  A61K39/295 ,  A61P37/04

Abstract: This disclosure relates to the field of preventing or treating virus infection, in particular, the disclosure relates to agents for vaccination against virus infection and inducing effective virus antigen-specific immune responses such as antibody and/or T cell responses and methods for generating and using such agents. Administration of agents such as RNA disclosed herein to a subject can protect the subject against virus infection. Specifically, the present disclosure relates to amino acid sequences comprising at least a portion of a virus protein having amino acid modifications found in other variants of the virus protein. Administration of RNA encoding one or more of the amino acid sequences may provide protection against diverse virus variants. Methods and agents described herein are, in particular, useful for the prevention or treatment of coronavirus infection such as SARS-CoV-2 infection.

公开(公告)号：US20240376221A1

公开(公告)日：2024-11-14

申请号：US18660672

申请日：2024-05-10

Applicant: Genmab A/S ,  BioNTech SE

Inventor： Kristel Kemper ,  Maarten van der Kroef ,  Dennis Verzijl ,  Andrea Gorlani ,  Pauline Linda de Goeje ,  Lars Guelen ,  David Satijn ,  Esther C. W. Breij ,  Ugur Sahin ,  Sina Fellermeier-Kopf ,  Maren Köhne

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K16/42

Abstract: The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20240339174A1

公开(公告)日：2024-10-10

申请号：US18289425

申请日：2022-05-04

Applicant: BioNTech SE ,  InstaDeep Ltd.

Inventor： Alexander Muik ,  Asaf Poran ,  Yunpeng Liu ,  Ugur Sahin ,  Karim Beguir ,  Marcin Skwark ,  Thomas Pierrot ,  Yunguan Fu

IPC: G16B20/20 ,  C07K14/005 ,  G16B15/30 ,  G16B40/20

CPC classification number: G16B20/20 ,  C07K14/005 ,  G16B15/30 ,  G16B40/20 ,  C12N2770/20022

Abstract: The present disclosure provides technologies for identifying, characterizing, and/or monitoring sequences of a variant of a reference infectious agent (e.g., but not limited to viral variants, for example in some embodiments SARS-CoV-2 variants) for transmissibility factors and/or immune escape potential, and/or for detecting and/or monitoring variants in environmental or biological samples, and/or for designing, preparing, and/or administering vaccines for such variants.

公开(公告)号：US12077596B2

公开(公告)日：2024-09-03

申请号：US17360438

申请日：2021-06-28

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Isil Altintas ,  David Satijn ,  Rik Rademaker ,  Paul Parren ,  Friederike Gieseke ,  Ugur Sahin

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/569

CPC classification number: C07K16/2878 ,  A61K39/3955 ,  G01N33/56972 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/92

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US11939388B2

公开(公告)日：2024-03-26

申请号：US17360437

申请日：2021-06-28

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Isil Altintas ,  David Satijn ,  Rik Rademaker ,  Paul Parren ,  Friederike Gieseke ,  Ugur Sahin

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/569

CPC classification number: C07K16/2878 ,  A61K39/3955 ,  G01N33/56972 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/92

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US20240042011A1

公开(公告)日：2024-02-08

申请号：US18186914

申请日：2023-03-20

Applicant: BioNTech SE

Inventor： Alexander Muik ,  Asaf Poran ,  Kena Anne Swanson ,  Qi Yang ,  Hui Cai ,  Ugur Sahin

IPC: A61K39/215 ,  A61K39/145 ,  A61K9/127 ,  A61K47/26 ,  C12N15/86

CPC classification number: A61K39/215 ,  A61K39/145 ,  A61K2039/545 ,  A61K47/26 ,  C12N15/86 ,  A61K9/1272

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

公开(公告)号：US20230330198A1

公开(公告)日：2023-10-19

申请号：US18333273

申请日：2023-06-12

Applicant: BioNTech SE ,  TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz

Inventor： Ugur Sahin ,  Sebastian Kreiter ,  Christina Krienke ,  Jutta Petschenka ,  Lena Mareen Kranz ,  Mustafa Diken

IPC: A61K39/00 ,  A61P37/06 ,  C12N15/11 ,  C12N15/117

CPC classification number: A61K39/0008 ,  A61P37/06 ,  C12N15/11 ,  C12N15/117 ,  A61K2039/53 ,  A61K2039/55555 ,  C12N2310/335

Abstract: The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.

公开(公告)号：US20230272406A1

公开(公告)日：2023-08-31

申请号：US17936377

申请日：2022-09-28

Applicant: BioNTech SE ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gG

Inventor： Alexandra Orlandini Von Niessen ,  Stephanie Fesser ,  Britta Vallazza ,  Tim Beissert ,  Andreas Kuhn ,  Ugur Sahin ,  Marco Alexander Poleganov

IPC: C12N15/67 ,  A47B3/00 ,  A47B13/02 ,  A47B33/00 ,  A47B43/00 ,  A47B77/02 ,  A47B77/06 ,  A47B77/08 ,  A47B77/16 ,  A47B77/18 ,  A47B95/00 ,  A47C4/00 ,  A47C4/08 ,  A47C7/00 ,  A47K3/28 ,  B60B33/00 ,  E04H1/12 ,  F16C11/04 ,  C12N5/0735 ,  C12N15/113 ,  C12N15/90

CPC classification number: C12N15/67 ,  A47B3/002 ,  A47B13/02 ,  A47B33/00 ,  A47B43/00 ,  A47B77/022 ,  A47B77/06 ,  A47B77/08 ,  A47B77/16 ,  A47B77/18 ,  A47B95/00 ,  A47B95/008 ,  A47C4/00 ,  A47C4/08 ,  A47C7/002 ,  A47C7/006 ,  A47K3/284 ,  B60B33/00 ,  E04H1/1266 ,  F16C11/04 ,  C12N5/0606 ,  C12N15/113 ,  C12N15/90 ,  A47B2003/006 ,  A47B2200/0018 ,  C12N2310/113

Abstract: The present invention relates to stabilization of RNA, in particular mRNA, and an increase in mRNA translation. The present invention particularly relates to a modification of RNA, in particular in vitro-transcribed RNA, resulting in increased transcript stability and/or translation efficiency. According to the invention, it was demonstrated that certain sequences in the 3′-untranslated region (UTR) of an RNA molecule improve stability and translation efficiency.